Ivermectin: a complimentary weapon against the spread of malaria?

Expert Review of Anti-Infective Therapy

Volumn 15, Issue 3, 2017, Pages 231-240

  Alout, Haoues ^a   Foy, Brian D ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

integrated control strategy; Ivermectin; lymphatic filariasis; malaria; mass drug administration; neglected infectious diseases; trials; vector control

Indexed keywords

IVERMECTIN; INSECTICIDE;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; IC50; IC90; INFECTION RISK; INSECTICIDE RESISTANCE; MALARIA; MALARIA CONTROL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARASITE CLEARANCE; PARASITE TRANSMISSION; PREVALENCE; REVIEW; ANIMAL; DISEASE TRANSMISSION; DRUG EFFECTS; INSECT VECTOR; MOSQUITO; PLASMODIUM; PREVENTION AND CONTROL; SEASON; TRANSMISSION;

ANIMALS; CULICIDAE; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; INSECT VECTORS; INSECTICIDE RESISTANCE; INSECTICIDES; IVERMECTIN; MALARIA; PLASMODIUM; SEASONS;

EID: 85013057137     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2017.1271713     Document Type: Review

References (69)

1. Watts G., Nobel awarded to discoverers of ivermectin and artemisinin. Bmj. 2015;351:5352.
2. Wilson ML. Avermectins in arthropod vector management - prospects and pitfalls. Parasitol Today. 1993;9(3):83–87.• This review highlighted, for the first time, how ivermectin should be researched as a way to affect the vectorial capacity of vectors.
3. Kane NS, Hirschberg B, Qian S, et al. Drug-resistant drosophila indicate glutamate-gated chloride channels are targets for the antiparasitics nodulisporic acid and ivermectin. Proc Natl Acad Sci. 2000;97(25):13949–13954.
4. Buckingham S, Biggin P, Sattelle B, et al. Insect GABA receptors:splicing, editing, and targeting by antiparasitics and insecticides. Mol Pharmacol. 2005;68(4):942–951.
5. Õmura S, Crump A, Omura S, et al. Timeline:the life and times of ivermectin — a success story. Nat Rev Microbiol. 2004;2(12):984–989.
6. CDC. Progress toward elimination of onchocerciasis in the Americas - 1993-2012. Mmwr. 2013;62(20):405–408.
7. Rebollo MP, Bockarie MJ. Toward the elimination of lymphatic filariasis by 2020:treatment update and impact assessment for the endgame. Expert Rev Anti Infect Ther. 2013;11(7):723–731.
8. Pampiglione S, Majori G, Petrangeli G, et al. Avermectins, mk-933 and mk-936, for mosquito control. Trans R Soc Trop Med Hyg. 1985;79(6):797–799.
9. Foy BD, Kobylinski KC, Da Silva IM, et al. Endectocides for malaria control. Trends Parasitol. 2011;27(10):423–428.• The first broad review of ivermectin for malaria transmission control.
10. Chaccour CJ, Kobylinski KC, Bassat Q, et al. Ivermectin to reduce malaria transmission:a research agenda for a promising new tool for elimination. Malar J. 2013;12(1):153.• A comprehensive review of the evidence of ivermectin for malaria transmission control which also laid out a future research agenda.
11. Elkassaby MH. Ivermectin uptake and distribution in the plasma and tissue of sudanese and mexican patients infected with Onchocerca volvulus. Trop Med Parasitol. 1991;42(2):79–81.
12. Ouédraogo AL, Bastiaens GJH, Tiono AB, et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment:a double-blind, randomized, clinical trial. Clin Infect Dis. 2015;60(3):357–365.•• The first paper to demonstrate that ivermectin combined with antimalarial drugs was free from increased harms and did not interfere with antimalarial drug efficacy, and that the blood from treated people killed malaria vectors.
13. Bockarie MJ, Hii JLK, Alexander NDE, et al. Mass treatment with ivermectin for filariasis control in papua new guinea:impact on mosquito survival. Med Vet Entomol. 1999;13(2):120–123.•• Though focused on lymphatic filariasis, this paper was the first to demonstrate in a field experiment that ivermectin treatment of villagers significantly reduced the survival of wild Anopheles vectors that blood fed on them.
14. Sylla M, Kobylinski KC, Gray M, et al. Mass drug administration of ivermectin in south-eastern senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malar J. 2010;9(1):365.• This paper mirrored the experiments of Bockarie et al. in the prior reference and was the first to demonstrate in a field experiment in Africa that IVM treatment of villagers significantly reduced the survival of wild Anopheles malaria vectors that blood fed on them.
15. Alout H, Krajacich BJ, Meyers JI, et al. Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malar J. 2014;13(1):417.•• This paper contained years of field data in West Africa that examined the affect of ivermectin on mosquito survival and on malaria transmission.
16. Fritz ML, Siegert PY, Walker ED, et al. Toxicity of bloodmeals from ivermectin-treated cattle to Anopheles gambiae s.l. Ann Trop Med Parasitol. 2009;103(6):539–547.
17. Pooda HS, Rayaisse J-B, Hien DF De S, et al. Administration of ivermectin to peridomestic cattle:a promising approach to target the residual transmission of human malaria. Malar J. 2015;14(1):496.
18. Rosenberg R. Malaria:some considerations regarding parasite productivity. Trends Parasitol. 2008 Nov;24(11):487-491.
19. Koella JC. On the use of mathematical models of malaria transmission. Acta Trop. 1991;49(1):1–25.
20. Slater HC, Walker PGT, Bousema T, et al. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission:a modelling study. J Infect Dis. 2014;210(12):1972–1980.• One of the first detailed modeling studies of ivermectin for malaria control.
21. Mueller I, Schoepflin S, Smith TA, et al. Force of infection is key to understanding the epidemiology of plasmodium falciparum malaria in papua new guinean children. Proc Natl Acad Sci. 2012;109(25):10030–10035.
22. Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207–211.
23. Kobylinski KC, Alout H, Foy BD, et al. Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control. Am J Trop Med Hyg. 2014;91(4):655–662.
24. Killeen GF. Characterizing, controlling and eliminating residual malaria transmission. Malar J. 2014;13:330.
25. Hooper PJ, Zoerhoff KL, Kyelem D, et al. Short report:the effects of integration on financing and coverage of neglected tropical disease programs. Am J Trop Med Hyg. 2013;89(3):407–410.
26. Cano J, Rebollo MP, Golding N, et al. The global distribution and transmission limits of lymphatic filariasis:past and present. Parasites and Vectors. 2014;7(1):466.
27. Brooker S. Epidemiology of plasmodium-helminth co-infections in Africa:population risk, potential impact on anaemia and prospects for combining control. Am J Trop Med Hyg. 2007;77(Suppl 6):88–98.
28. Raviglione MC, Uplekar MW. WHO’s new stop tb strategy. Lancet. 2006;367(9514):952–955.
29. Duke BO, Zea-Flores G, Castro J, et al. Comparison of the effects of a single dose and of four six-monthly doses of ivermectin on adult Onchocerca volvulus. Am J Trop Med Hyg. 1991;45(1):132–137.
30. Torres JR, Isturiz R, Murillo J, et al. Efficacy of ivermectin in the treatment of strongyloidiasis complicating AIDS. Clin Infect Dis. 1993;17(5):900–902.
31. Awadzi K, Opoku NO, Addy ET, et al. The chemotherapy of onchocerciasis. the clinical and laboratory tolerance of high-dose ivermectin. Trop Med Parasitol. 1995;46(2):131–137.
32. Kamgno J, Gardon J, Gardon-Wendel N, et al. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Trans R Soc Trop Med Hyg. 2004;98(8):496–504.
33. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122–1133.
34. Chaccour C, et al. Screening for an ivermectin slow-release formulation suitable for malaria vector control. Malar J. 2015;14:102.
35. Plaisier AP, Stolk WA, Van Oortmarssen GJ, et al. Effectiveness of annual ivermectin treatment for wuchereria bancrofti infection. Parasitol Today. 2000;16(7):298–302.
36. Sodahlon YK, Dorkenoo AM, Morgah K, et al. A success story:togo is moving toward becoming the first sub-saharan African nation to eliminate lymphatic filariasis through mass drug administration and countrywide morbidity alleviation. Plos Negl Trop Dis. 2013;7(4):e2080.
37. Da Cruz FP, Martin C, Buchholz K, et al. Drug screen targeted at plasmodium liver stages identifies a potent multistage antimalarial drug. J Infect Dis. 2012;205(8):1278–1286.•• Though in a mouse model, this paper provided the first evidence of a direct anti-Plasmodium effect of ivermectin on liver stage forms.
38. Mendes A.M., et al. Inhibition of Plasmodium liver infection by ivermectin. Antimicrob Agents Chemother. 2016.
39. Panchal M, Rawat K, Kumar G, et al. Plasmodium falciparum signal recognition particle components and anti-parasitic effect of ivermectin in blocking nucleo-cytoplasmic shuttling of SRP. Cell Death Dis. 2014;5:e994.
40. Nasveld P, Russell B, Kotecka B, et al. Lack of in vitro effect of ivermectin on plasmodium falciparum. Southeast Asian J Trop Med Public Health. 2003;34(3):552–553.
41. Lariviere M, Beauvais B, Aziz M, et al. [A study in the ivory coast (1985-1987) of the efficacy and tolerance of ivermectin (mectizan) in human onchocerciasis. I. A comparative double-blind study of 220 patients with onchocerciasis treated with a single oral dose of 100, 150 or 200 mcg/kg]. Bull Soc Pathol Exot Filiales. 1989;82(1):35–47.
42. Kobylinski KC, Foy BD, Richardson JH. Ivermectin inhibits the sporogony of plasmodium falciparum in Anopheles gambiae. Malar J. 2012;11:381.• Provided the first evidence of an anti-Plasmodium effect of ivermectin on forms present in the mosquito.
43. Lambrechts L, Halbert J, Durand P, et al. Host genotype by parasite genotype interactions underlying the resistance of anopheline mosquitoes to. Plasmodium Falciparum Insect Mol Biol. 2005;4:3.
44. Cohuet A, Osta MA, Morlais I, et al. Anopheles and plasmodium:from laboratory models to natural systems in the field. EMBO Rep. 2006;7(12):1285–1289.
45. Harris C, Morlais I, Churcher TS, et al. Plasmodium falciparum produce lower infection intensities in local versus foreign Anopheles gambiae populations. Plos One. 2012;7:(1), e30849.
46. Coccini T, Candura SM, Manzo L, et al. Interaction of the neurotoxic pesticides ivermectin and lindane with the enteric GABA A receptor-ionophore complex in the guinea-pig. Eur J Pharmacol Environ Toxicol. 1993;248(1):1–6.
47. Tonini M, Costa LG, Candura SM, et al. Interaction of the pyrethroid insecticides tetramethrin and cypermethrin with enteric cholinergic transmission in the guinea-pig. Neurotoxicology. 1989;10(4):707–715.
48. Sreeramulu K, Liu R, Sharom FJ. Interaction of insecticides with mammalian P-glycoprotein and their effect on its transport function. Biochim Biophys Acta. 2007;1768:1750–1757.
49. Podsiadlowski L, Matha V, Vilcinskas A. Detection of a P-glycoprotein related pump in chironomus larvae and its inhibition by verapamil and cyclosporin A. Comp Biochem Physiol Part B Biochem Mol Biol. 1998;121(4):443–450.
50. Lecoeur S, Videmann B, Mazallon M. Effect of organophosphate pesticide diazinon on expression and activity of intestinal P-glycoprotein. Toxicol Lett. 2006;161(3):200–209.
51. Agarwala S, Chen W, Cook TJ. Effect of chlorpyrifos on efflux transporter gene expression and function in caco-2 cells. Toxico Vitr. 2004;18(4):403–409.
52. Shabbir A, DiStasio S, Zhao J, et al. Differential effects of the organochlorine pesticide DDT and its metabolite p,p′-DDE on p-glycoprotein activity and expression. Toxicol Appl Pharmacol. 2005;203(2):91–98.
53. Griffin J, Fletcher N, Clemence R, et al. Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. J Vet Pharmacol Ther. 2005;28(3):257–265.
54. Bain LJ, LeBlanc GA. Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein. Toxicol Appl Pharmacol. 1996;141(1):288–298.
55. Buss DS, McCaffery AR, Callaghan A. Evidence for p-glycoprotein modification of insecticide toxicity in mosquitoes of the Culex pipiens complex. Med Vet Entomol. 2002;16:218–222.
56. Yoon KS, Strycharz JP, Baek JH, et al. Brief exposures of human body lice to sublethal amounts of ivermectin over-transcribes detoxification genes involved in tolerance. Insect Mol Biol. 2011;20(6):687–699.
57. Deus KM, Saavedra-Rodriguez K, Butters MP, et al. The effect of ivermectin in seven strains of Aedes aegypti (diptera:culicidae) including a genetically diverse laboratory strain and three permethrin resistant strains. J Med Entomol. 2012;49(2):356–363.
58. Martinez-Torres D, Chandre F, Williamson MS, et al. Molecular characterization of pyrethroid knockdown resistance (kdr) in the major malaria vector Anopheles gambiae s.s. Insect Mol Biol. 1998;7(2):179–184.
59. Blackhall WJ, Liu HY, Xu M, et al. Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of haemonchus contortus. Mol Biochem Parasitol. 1998;95(2):193–201.
60. Njue AI, Prichard RK. Genetic variability of glutamate-gated chloride channel genes in ivermectin-susceptible and -resistant strains of cooperia oncophora. Parasitology. 2004;129(6):741–751.
61. Geerts S, Gryseels B. Drug resistance in human helminths:current situation and lessons from livestock. Clin Microbiol Rev. 2000;13(2):207–222.
62. Currie BJ, Harumal P, McKinnon M, et al. First documentation of in vivo and in vitro ivermectin resistance in sarcoptes scabiei. Clin Infect Dis. 2004;39(1):8–12.
63. Osei-Atweneboana MY, Awadzi K, Attah SK, et al. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. Plos Negl Trop Dis. 2011;5(3):e998.
64. Thomsen EK, Sanuku N, Baea M, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis. 2016;62(3):334–341.
65. Kobylinski KC, Deus KM, Butters MP, et al. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 2010;116(2):119–126.
66. Kaplan RM, Vidyashankar AN. An inconvenient truth:global worming and anthelmintic resistance. Vet Parasitol. 2012;186(1–2):70–78.
67. Seaman JA, Alout H, Meyers JI, et al. Age and prior blood feeding of Anopheles gambiae influences their susceptibility and gene expression patterns to ivermectin-containing blood meals. BMC Genomics. 2015;16(1):797.
68. Scott TW, et al. DNA profiling of human blood in anophelines from lowland and highland sites in Western Kenya. Am J Trop Med Hyg. 2006;75(2):231–237.
69. Stone W, Gonçalves BP, Bousema T, et al. Assessing the infectious reservoir of falciparum malaria:past and future. Trends Parasitol. 2015;31(7):287–296.